Ron Kocak Biography and Net Worth

Vice President of Finance and Controller of RenovoRx

Mr. Kocak is a seasoned financial reporting and accounting professional with extensive public company experience in the life sciences industry. Mr. Kocak has served as RenovoRx’s interim controller in a consulting capacity since October 2021. Prior to joining RenovoRx, Mr. Kocak was Controller and Senior Director of Finance at Sensei Biotherapeutics, Inc., where he successfully led the finance and accounting activities, including the IT operations. He holds a Bachelor of Science in accounting from Duquesne University and a CPA license in the Commonwealth of Virginia. Mr. Kocak is also a member of the American Institute of Certified Public Accountants and Association of Bioscience Financial Officers, and a Chartered Global Management Accountant.

What is Ron Kocak's net worth?: The estimated net worth of Ron Kocak is at least $21.59 thousand as of April 10th, 2025. Mr. Kocak owns 12,595 shares of RenovoRx stock worth more than $21,588 as of September 18th. This net worth evaluation does not reflect any other assets that Mr. Kocak may own. Learn More about Ron Kocak's net worth.
How do I contact Ron Kocak?: The corporate mailing address for Mr. Kocak and other RenovoRx executives is 2570 W. EL Camino Real, Ste. 320,, Mountain View, CA, 94040. RenovoRx can also be reached via phone at (408) 800-2649 and via email at [email protected]. Learn More on Ron Kocak's contact information.
Has Ron Kocak been buying or selling shares of RenovoRx?: Ron Kocak has not been actively trading shares of RenovoRx during the last ninety days. Most recently, on Thursday, April 10th, Ron Kocak bought 6,500 shares of RenovoRx stock. The stock was acquired at an average cost of $0.79 per share, with a total value of $5,135.00. Following the completion of the transaction, the vice president now directly owns 12,595 shares of the company's stock, valued at $9,950.05. Learn More on Ron Kocak's trading history.
Who are RenovoRx's active insiders?: RenovoRx's insider roster includes Ramtin Agah (Insider), Ron Kocak (Vice President of Finance and Controller), Laurence Marton (Director), and Mark Voll (CFO). Learn More on RenovoRx's active insiders.
Are insiders buying or selling shares of RenovoRx?: In the last year, RenovoRx insiders bought shares 9 times. They purchased a total of 94,000 shares worth more than $79,993.85. The most recent insider tranaction occured on May, 19th when CFO Mark Voll bought 25,000 shares worth more than $19,750.00. Insiders at RenovoRx own 9.4% of the company. Learn More about insider trades at RenovoRx.
Information on this page was last updated on 5/19/2026.

Ron Kocak Insider Trading History at RenovoRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/10/2025	Buy	6,500	$0.79	$5,135.00	12,595
4/8/2025	Buy	95	$0.80	$76.00	95

Ron Kocak Buying and Selling Activity at RenovoRx

RenovoRx Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Today's Range

Now: $1.70

$1.67

$1.75

50 Day Range

MA: $1.35

$0.85

$2.52

2 Week Range

Now: $1.70

$0.70

$2.59

Volume

388,854 shs

Average Volume

459,926 shs

Market Capitalization

$76.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12